AstraZeneca enjoys broad but not universal analyst support. Roughly a dozen current, attributable price targets were reviewed, spanning from approximately $154 to $240. The arithmetic mean of those targets is approximately $207, which is the figure used as the central target throughout this article. Brokerage views remain predominantly constructive: recent coverage shows about 15 Buy or Overweight ratings against two to three Holds, with Deutsche Bank a notable cautious outlier.
Reasoning behind the targets differs meaningfully. Bulls such as TD Cowen ($240) and Citi (around $235) emphasize above-peer EPS growth and selective pipeline upside, while Goldman Sachs ($219) and Bank of America (about $218) point to the oncology strategy. More cautious firms, including Deutsche Bank (about $154–$156) and HSBC (about $184), cite patent expirations and a full valuation. The wide low-to-high spread underscores that the $207 average is a midpoint of divergent opinions, not a forecast or a guarantee.
AstraZeneca shares recently traded near $171.50, close to the midpoint of a 52-week range of roughly $153 to $213. Reaching the $207 central target would require a move of about 21%, which is substantial for a company of this size. The stock has been consolidating below its 200-day moving average after a strong run earlier in the year, so the path to $207 would likely depend less on a single event and more on sustained earnings delivery and continued pipeline validation.
Fundamentally, the company has guided to mid-to-high single-digit revenue growth and low double-digit core EPS growth. Its most recent quarter showed EPS that beat expectations even as revenue came in slightly below estimates, reflecting steady rather than explosive momentum. Valuation also matters: the shares trade near the upper teens on forward earnings, in line with large oncology peers, so multiple expansion would need to be justified by earnings rather than sentiment alone.
The shares have respected a well-defined trading range. Support sits near the 52-week low around $153–$156, a zone that also coincides with the lowest analyst targets. On the upside, $200 is a notable psychological resistance level that clusters with several analyst targets, while the 52-week high near $213 represents the next major overhead barrier. A sustained move above $200 would put the $207 central target within reach, whereas a break below the $153 support level would suggest the bullish case is weakening.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms apply different frameworks and timelines, which is part of why the target range is so wide. Investors should watch upcoming quarterly results, including revenue and core EPS against guidance; updates on the oncology pipeline and regulatory decisions; any shifts in analyst target revisions; and broader drug-pricing policy developments. Guidance revisions on revenue and core EPS growth will be the clearest near-term signals of whether the earnings base can support a higher share price.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a large-cap name like AstraZeneca, these signals can help traders spot shifting momentum and identify turning points more efficiently than manual chart review. Traders can use the tool to discover new opportunities, monitor existing positions, and stay ahead of changing trends. Explore the AI Daily Buy/Sell Signals to see how data-driven timing can complement fundamental research.
The $207 target for AstraZeneca is a calculated average of analyst price targets, not a published consensus or a forecast. It sits roughly 21% above the current share price and falls comfortably inside the wide $154-to-$240 range of individual estimates. The case for reaching it rests on durable oncology growth, a productive pipeline, and double-digit EPS expansion, while the case against it rests on patent cliffs, pricing pressure, and a valuation that is full rather than discounted. With substantial analyst disagreement and the shares trading below their 200-day moving average, the next earnings prints and pipeline readouts will determine whether the path toward $207 remains credible.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AZN | 1D Price Change % | ||
|---|---|---|---|---|
| AZN | 100% | +7.02% | ||
| BIIB - AZN | 48% Loosely correlated | +1.59% | ||
| GILD - AZN | 39% Loosely correlated | +3.06% | ||
| GSK - AZN | 26% Poorly correlated | +1.71% | ||
| MRK - AZN | 26% Poorly correlated | +2.18% | ||
| NVS - AZN | 25% Poorly correlated | -0.19% | ||
More | ||||